Results 1 to 10 of about 3,356,787 (275)

Phosphodiesterase inhibitors in psychiatric disorders

Psychopharmacology, 2023
Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
M. Sadeghi, Ehsan Nassireslami, Mojtaba Yousefi Zoshk, Yasaman Hosseini, Kourosh Abbasian, Mohsen Chamanara   +5 more
semanticscholar   +3 more sources

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2017
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema Zebda, A. Paller
semanticscholar   +3 more sources

Xanthines and Phosphodiesterase Inhibitors.

Handbook of Experimental Pharmacology, 2017
Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D. Spina, Clive P. Page
semanticscholar   +3 more sources

Phosphodiesterase inhibitors say NO to Alzheimer's disease.

Food and Chemical Toxicology, 2019
Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions.
S. Nabavi, Sylwia Talarek, J. Listos, S. Nabavi, K. P. Devi, Marcos Roberto de Oliveira, Devesh Tewari, S. Argüelles, S. Mehrzadi, A. Hosseinzadeh, G. D’Onofrio, I. Orhan, A. Sureda, Suowen Xu, S. Momtaz, M. Farzaei   +15 more
semanticscholar   +1 more source

Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.

Journal of Medicinal Chemistry, 2018
Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu, Hai-bin Luo   +4 more
semanticscholar   +1 more source

A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017
R. Shafiee-Nick, A. Afshari, S. Mousavi, A. Rafighdoust, V. Askari, H. Mollazadeh, Sahar Fanoudi, E. Mohtashami, V. Rahimi, Moein Mohebbi, M. Vahedi   +10 more
semanticscholar   +1 more source

Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.

Bioorganic & Medicinal Chemistry, 2016
S. S. Laev, N. Salakhutdinov, O. Lavrik
semanticscholar   +1 more source

Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson’s Disease?

Molecular Neurobiology, 2016
D. N. Nthenge-Ngumbau, K. Mohanakumar
semanticscholar   +1 more source

Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.

Sexual Medicine Reviews, 2017
F. Yafi, I. Sharlip, E. Becher
semanticscholar   +1 more source

Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites.

ACS Chemical Biology, 2015
B. L. Howard, Katherine L. Harvey, R. J. Stewart, M. F. Azevedo, B. Crabb, I. Jennings, P. Sanders, D. Manallack, P. Thompson, C. Tonkin, P. Gilson   +10 more
semanticscholar   +1 more source